TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Communiqué de presse : Sanofi finalise l’acquisition de Vicebio

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Sanofi
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio

Sanofi has completed the acquisition of Vicebio, a biotechnology company, adding a combined vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) to its vaccine development pipeline.

Insights
NFLX   positive

80.93% institutional ownership, 94% net income increase from 2022 to 2024, sustainable profitability, low short interest


SNY   positive

The acquisition expands Sanofi's vaccine development capabilities and pipeline, offering a non-mRNA vaccine option for RSV and HMPV prevention